Vieira Roberto Wandenkolk sold $967K of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.10 ($114.52–$116.58, $0.97M total) across 3 trades on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Oct 5, 2026, 11:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a mild bearish indicator, though the amount is modest.

02

Market read

A routine insider sell of under $1M, modestly reducing insider stake; limited trading relevance.

03

What to watch

No new product or trial data disclosed; the transaction is isolated.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; investors monitor these for potential signals.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

President of Oncology sold 8,333 shares for $967K via a 10b5‑1 plan, reducing his stake to 3,946 shares.

Expected impact

likely pressure as investors price in the insider sell

Evidence & confidence

The sale is a routine 10b5‑1 transaction of under $1M; market may view it as a slight bearish cue.

Market effects

Minimal impact on biotech sector; typical insider transaction.

None

None

Counterpoint

The sale could be purely procedural; no change in fundamentals.

Key entities

  • Corcept Therapeutics Inc

    Biopharma focused on cortisol‑related therapies, ticker CORT.

  • Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.